Literature DB >> 12226093

Truncation of CDK5 activator p35 induces intensive phosphorylation of Ser202/Thr205 of human tau.

Mitsuko Hashiguchi1, Taro Saito, Shin-ichi Hisanaga, Toshio Hashiguchi.   

Abstract

Hyperphosphorylated tau is a major component of neurofibrillary tangles, one of the hallmarks of Alzheimer's disease. CDK5 is a kinase that phosphorylates the tau protein, and its endogenous activator, p35, regulates its activity. Recently, calpain was found to digest p35 to its truncated product, p25. Several lines of evidence suggest that p25-CDK5 has much more powerful kinase activity and that it may cause abnormal hyperphosphorylation of tau. In this study, we have examined the kinetic characteristics of in vitro phosphorylation of the longest isoform of human tau by CDK5 and its activators using recombinant proteins. Although the kinase activity of CDK5 in phosphorylating tau was significantly higher in the presence of p25, the affinity of CDK5 for tau was not different. Phosphopeptide mapping revealed enhanced phosphorylation of Ser(202)/Thr(205) residues by p25-CDK5 (amino acid residues of tau are numbered according to the longest isoform of human tau). These results suggest that cleavage of p35 to p25 greatly enhances the kinase activity of CDK5 and increases the phosphorylation of Ser(202)/Thr(205). Considering the fact that phosphorylation of Ser(202)/Thr(205) antagonizes the tau-mediated nucleation of tubulin, p25-CDK5 may play a pivotal role in neuronal cell death in Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12226093     DOI: 10.1074/jbc.M207426200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  45 in total

1.  Role of activation of PIP5Kgamma661 by AP-2 complex in synaptic vesicle endocytosis.

Authors:  Akiko Nakano-Kobayashi; Masakazu Yamazaki; Takamitsu Unoki; Tsunaki Hongu; Chie Murata; Ryo Taguchi; Toshiaki Katada; Michael A Frohman; Takeaki Yokozeki; Yasunori Kanaho
Journal:  EMBO J       Date:  2007-02-08       Impact factor: 11.598

Review 2.  Tau as a therapeutic target for Alzheimer's disease.

Authors:  A Boutajangout; E M Sigurdsson; P K Krishnamurthy
Journal:  Curr Alzheimer Res       Date:  2011-09       Impact factor: 3.498

Review 3.  Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.

Authors:  Yoshinari Miyata; John Koren; Janine Kiray; Chad A Dickey; Jason E Gestwicki
Journal:  Future Med Chem       Date:  2011-09       Impact factor: 3.808

4.  Quantum capacitance-limited MoS2 biosensors enable remote label-free enzyme measurements.

Authors:  Son T Le; Nicholas B Guros; Robert C Bruce; Antonio Cardone; Niranjana D Amin; Siyuan Zhang; Jeffery B Klauda; Harish C Pant; Curt A Richter; Arvind Balijepalli
Journal:  Nanoscale       Date:  2019-08-13       Impact factor: 7.790

5.  A Cdk5 inhibitory peptide reduces tau hyperphosphorylation and apoptosis in neurons.

Authors:  Ya-Li Zheng; Sashi Kesavapany; Maneth Gravell; Rebecca S Hamilton; Manfred Schubert; Niranjana Amin; Wayne Albers; Philip Grant; Harish C Pant
Journal:  EMBO J       Date:  2004-12-09       Impact factor: 11.598

Review 6.  Deregulated Cdk5 activity is involved in inducing Alzheimer's disease.

Authors:  Varsha Shukla; Susan Skuntz; Harish C Pant
Journal:  Arch Med Res       Date:  2012-11-07       Impact factor: 2.235

7.  Special Issue on "Cdk5 and Brain Disorders": Prologue.

Authors:  Jyotshnabala Kanungo
Journal:  Brain Disord Ther       Date:  2012-05-31

8.  Partial rescue of the p35-/- brain phenotype by low expression of a neuronal-specific enolase p25 transgene.

Authors:  Holger Patzke; Upendra Maddineni; Ramses Ayala; Maria Morabito; Janet Volker; Pieter Dikkes; Michael K Ahlijanian; Li-Huei Tsai
Journal:  J Neurosci       Date:  2003-04-01       Impact factor: 6.167

9.  Cdk5 phosphorylation of EFhd2 at S74 affects its calcium binding activity.

Authors:  Edwin Vázquez-Rosa; Eva N Rodríguez-Cruz; Sybelle Serrano; Lucelenie Rodríguez-Laureano; Irving E Vega
Journal:  Protein Sci       Date:  2014-06-18       Impact factor: 6.725

10.  Inhibition of p25/Cdk5 Attenuates Tauopathy in Mouse and iPSC Models of Frontotemporal Dementia.

Authors:  Jinsoo Seo; Oleg Kritskiy; L Ashley Watson; Scarlett J Barker; Dilip Dey; Waseem K Raja; Yuan-Ta Lin; Tak Ko; Sukhee Cho; Jay Penney; M Catarina Silva; Steven D Sheridan; Diane Lucente; James F Gusella; Bradford C Dickerson; Stephen J Haggarty; Li-Huei Tsai
Journal:  J Neurosci       Date:  2017-09-14       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.